These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
161 related items for PubMed ID: 25027109
1. Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial. Binkley N, Bone H, Gilligan JP, Krause DS. Osteoporos Int; 2014 Nov; 25(11):2649-56. PubMed ID: 25027109 [Abstract] [Full Text] [Related]
2. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators. J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792 [Abstract] [Full Text] [Related]
3. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, Bonnick S, van den Bergh JP, Ferreira I, Dakin P, Wagman RB, Recknor C. Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847 [Abstract] [Full Text] [Related]
4. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. Henriksen K, Byrjalsen I, Andersen JR, Bihlet AR, Russo LA, Alexandersen P, Valter I, Qvist P, Lau E, Riis BJ, Christiansen C, Karsdal MA, SMC021 investigators. Bone; 2016 Oct; 91():122-9. PubMed ID: 27462009 [Abstract] [Full Text] [Related]
5. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis. Zhu HM, Qin L, Garnero P, Genant HK, Zhang G, Dai K, Yao X, Gu G, Hao Y, Li Z, Zhao Y, Li W, Yang J, Zhao X, Shi D, Fuerst T, Lu Y, Li H, Zhang X, Li C, Zhao J, Wu Q, Zhao SJ. Osteoporos Int; 2012 Apr; 23(4):1317-27. PubMed ID: 21505910 [Abstract] [Full Text] [Related]
6. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study. Liang BC, Shi ZY, Wang B, Wu P, Kong LC, Yao JL, Li CW, Shi XL. Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638 [Abstract] [Full Text] [Related]
7. Which is the preferred site for bone mineral density monitoring as an indicator of treatment-related anti-fracture effect in routine clinical practice? A registry-based cohort study. Leslie WD, Martineau P, Bryanton M, Lix LM. Osteoporos Int; 2019 Jul; 30(7):1445-1453. PubMed ID: 31016351 [Abstract] [Full Text] [Related]
8. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, Cormier C, Isaia G, Badurski J, Wark JD, Collette J, Reginster JY. Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678 [Abstract] [Full Text] [Related]
9. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women. Rizzoli R, Sigaud A, Azria M, Herrmann FR. Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730 [Abstract] [Full Text] [Related]
10. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP, Benhamou CL, Felsenberg D, Diaz-Curiel M, Brandi ML, Badurski J, Wark J, Balogh A, Bruyère O, Roux C. Osteoporos Int; 2012 Mar; 23(3):1115-22. PubMed ID: 22124575 [Abstract] [Full Text] [Related]
11. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study. Nakamura T, Shiraki M, Fukunaga M, Tomomitsu T, Santora AC, Tsai R, Fujimoto G, Nakagomi M, Tsubouchi H, Rosenberg E, Uchida S. Osteoporos Int; 2014 Jan; 25(1):367-76. PubMed ID: 23716037 [Abstract] [Full Text] [Related]
12. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, Papapoulos S, Shih WJ, Rybak-Feiglin A, Santora AC, Verbruggen N, Leung AT, Lombardi A. Osteoporos Int; 2015 Feb; 26(2):699-712. PubMed ID: 25432773 [Abstract] [Full Text] [Related]
13. Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Nakamura T, Matsumoto T, Sugimoto T, Shiraki M. Osteoporos Int; 2012 Mar; 23(3):1131-40. PubMed ID: 21927920 [Abstract] [Full Text] [Related]
14. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S. Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148 [Abstract] [Full Text] [Related]
15. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study. Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K. Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969 [Abstract] [Full Text] [Related]
16. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis. McClung MR, Lippuner K, Brandi ML, Zanchetta JR, Bone HG, Chapurlat R, Hans D, Wang A, Zapalowski C, Libanati C. Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386 [Abstract] [Full Text] [Related]
17. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension. Zhang ZL, Liao EY, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, De Peng Y, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L, Santora AC. Osteoporos Int; 2015 Sep; 26(9):2365-74. PubMed ID: 25929192 [Abstract] [Full Text] [Related]
18. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis. Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, Beck-Peccoz P, Chiodini I. Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095 [Abstract] [Full Text] [Related]
19. Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis. Black DM, Bilezikian JP, Greenspan SL, Wüster C, Muñoz-Torres M, Bone HG, Rosen CJ, Andersen HS, Hanley DA. Osteoporos Int; 2013 Apr; 24(4):1503-11. PubMed ID: 22930240 [Abstract] [Full Text] [Related]
20. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates. Cosman F, Gilchrist N, McClung M, Foldes J, de Villiers T, Santora A, Leung A, Samanta S, Heyden N, McGinnis JP, Rosenberg E, Denker AE. Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736 [Abstract] [Full Text] [Related] Page: [Next] [New Search]